These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 28960490)

  • 1. Safety of secukinumab in hepatitis B virus.
    Bevans SL; Mayo TT; Elewski BE
    J Eur Acad Dermatol Venereol; 2018 Mar; 32(3):e120-e121. PubMed ID: 28960490
    [No Abstract]   [Full Text] [Related]  

  • 2. Secukinumab for psoriasis in a patient with hepatitis B.
    Feaster B; Cline A; Feldman SR
    Dermatol Online J; 2018 Sep; 24(9):. PubMed ID: 30677838
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety of secukinumab in the treatment of psoriasis.
    Blauvelt A
    Expert Opin Drug Saf; 2016 Oct; 15(10):1413-20. PubMed ID: 27545070
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety Profile of Secukinumab in Treatment of Patients with Psoriasis and Concurrent Hepatitis B or C: A Multicentric Prospective Cohort Study.
    Chiu HY; Hui RC; Huang YH; Huang RY; Chen KL; Tsai YC; Lai PJ; Wang TS; Tsai TF
    Acta Derm Venereol; 2018 Oct; 98(9):829-834. PubMed ID: 29972221
    [TBL] [Abstract][Full Text] [Related]  

  • 5. COSENTYX (Secukinumab).
    Gupta AK; Foley KA; Abramovits W
    Skinmed; 2015; 13(4):303-6. PubMed ID: 26861430
    [No Abstract]   [Full Text] [Related]  

  • 6. Interleukin-17 (IL-17) inhibitors in the treatment of plaque psoriasis: a review.
    Gooderham M; Posso-De Los Rios CJ; Rubio-Gomez GA; Papp K
    Skin Therapy Lett; 2015; 20(1):1-5. PubMed ID: 25807214
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Secukinumab: a review in moderate to severe plaque psoriasis.
    Garnock-Jones KP
    Am J Clin Dermatol; 2015 Aug; 16(4):323-330. PubMed ID: 26202871
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of secukinumab in patients with generalized pustular psoriasis: A 52-week analysis from phase III open-label multicenter Japanese study.
    Imafuku S; Honma M; Okubo Y; Komine M; Ohtsuki M; Morita A; Seko N; Kawashima N; Ito S; Shima T; Nakagawa H
    J Dermatol; 2016 Sep; 43(9):1011-7. PubMed ID: 26919410
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Secukinumab: A positive outcome in a patient with severe psoriasis and HBV-HCV co-infection.
    Peccerillo F; Odorici G; Pellacani G; Conti A
    Dermatol Ther; 2018 Jul; 31(4):e12601. PubMed ID: 29633448
    [No Abstract]   [Full Text] [Related]  

  • 10. Secukinumab in plaque psoriasis--results of two phase 3 trials.
    Langley RG; Elewski BE; Lebwohl M; Reich K; Griffiths CE; Papp K; Puig L; Nakagawa H; Spelman L; Sigurgeirsson B; Rivas E; Tsai TF; Wasel N; Tyring S; Salko T; Hampele I; Notter M; Karpov A; Helou S; Papavassilis C; ;
    N Engl J Med; 2014 Jul; 371(4):326-38. PubMed ID: 25007392
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Psoriasis. Inhibition of IL-17 signaling pathway by Secukinumab].
    Recker K
    Med Monatsschr Pharm; 2014 Jul; 37(7):267-8. PubMed ID: 25065169
    [No Abstract]   [Full Text] [Related]  

  • 12. Secukinumab: IL-17A inhibition to treat psoriatic arthritis.
    Speeckaert R; van Geel N; Lambert J; Claeys L; Delanghe JR; Speeckaert MM
    Drugs Today (Barc); 2016 Nov; 52(11):607-616. PubMed ID: 28112279
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acute Generalized Pustular Psoriasis Treated With the IL-17A Antibody Secukinumab.
    Böhner A; Roenneberg S; Eyerich K; Eberlein B; Biedermann T
    JAMA Dermatol; 2016 Apr; 152(4):482-4. PubMed ID: 26650014
    [No Abstract]   [Full Text] [Related]  

  • 14. Secukinumab (AIN-457) for the treatment of Psoriasis.
    Jaleel T; Elmets C; Weinkle A; Kassira S; Elewski B
    Expert Rev Clin Pharmacol; 2016; 9(2):187-202. PubMed ID: 26647300
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of switching to ixekizumab in secukinumab nonresponders with plaque psoriasis: A multicenter retrospective study of interleukin 17A antagonist therapies.
    Georgakopoulos JR; Phung M; Ighani A; Yeung J
    J Am Acad Dermatol; 2018 Jul; 79(1):155-157. PubMed ID: 29307635
    [No Abstract]   [Full Text] [Related]  

  • 16. Meta-analysis of the Efficacy and Safety of Secukinumab for the Treatment of Plaque Psoriasis.
    Ryoo JY; Yang HJ; Ji E; Yoo BK
    Ann Pharmacother; 2016 May; 50(5):341-51. PubMed ID: 26783352
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and Safety of Secukinumab in Elderly Subjects with Moderate to Severe Plaque Psoriasis: A Pooled Analysis of Phase III Studies.
    Körber A; Papavassilis C; Bhosekar V; Reinhardt M
    Drugs Aging; 2018 Feb; 35(2):135-144. PubMed ID: 29404966
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Secukinumab (Cosentyx) for psoriasis.
    Med Lett Drugs Ther; 2015 Mar; 57(1465):45-7. PubMed ID: 25853578
    [No Abstract]   [Full Text] [Related]  

  • 19. Anti IL-17 flared psoriasis in a patient on secukinumab.
    Noell C; McQuade B; Gottlieb A; Rosmarin D
    Dermatol Ther; 2017 Jul; 30(4):. PubMed ID: 28547879
    [No Abstract]   [Full Text] [Related]  

  • 20. Three cases of facial erythema with dryness and pruritus in psoriasis patients during treatment with IL-17 inhibitors.
    Oiwa T; Honda T; Otsuka A; Kabashima K
    J Eur Acad Dermatol Venereol; 2018 Apr; 32(4):e122-e123. PubMed ID: 28983980
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.